Understanding the phenotypic variability in Niemann-Pick disease type C (NPC): a need for precision medicine

M Las Heras, B Szenfeld, RA Ballout, E Buratti… - NPJ Genomic …, 2023 - nature.com
Abstract Niemann-Pick type C (NPC) disease is a lysosomal storage disease (LSD)
characterized by the buildup of endo-lysosomal cholesterol and glycosphingolipids due to …

Treatment trials in Niemann-Pick type C disease

D Sitarska, A Tylki-Szymańska, A Ługowska - Metabolic Brain Disease, 2021 - Springer
Abstract Niemann-Pick type C (NPC) disease is a genetically determined
neurodegenerative metabolic disease. It belongs to the lysosomal storage diseases and its …

Lysosomal and mitochondrial liaisons in Niemann-Pick disease

S Torres, E Balboa, S Zanlungo, C Enrich… - Frontiers in …, 2017 - frontiersin.org
Lysosomal storage disorders (LSD) are characterized by the accumulation of diverse lipid
species in lysosomes. Niemann-Pick type A/B (NPA/B) and type C diseases Niemann-Pick …

The complexity of a monogenic neurodegenerative disease: More than two decades of therapeutic driven research into Niemann-Pick type C disease

N Hammond, AB Munkacsi, SL Sturley - Biochimica et Biophysica Acta …, 2019 - Elsevier
Abstract Niemann-Pick type C (NP-C) disease is a rare and fatal neurodegenerative disease
typified by aberrations in intracellular lipid transport. Cholesterol and other lipids accumulate …

Repurposing vorinostat for the treatment of disorders affecting brain

KV Athira, P Sadanandan, S Chakravarty - Neuromolecular Medicine, 2021 - Springer
Based on the findings in recent years, we summarize the therapeutic potential of vorinostat
(VOR), the first approved histone deacetylase (HDAC) inhibitor, in disorders of brain, and …

Animal models for Niemann-Pick type C: implications for drug discovery & development

CK Fog, T Kirkegaard - Expert opinion on drug discovery, 2019 - Taylor & Francis
ABSTRACT Introduction: Niemann-Pick type C (NPC) is a neurovisceral, progressively
detrimental lysosomal storage disease with very limited therapeutic options and no …

[HTML][HTML] Identification of a histone deacetylase inhibitor as a therapeutic candidate for congenital central hypoventilation syndrome

C Africano, T Bachetti, P Uva, G Pitollat… - … Therapy Nucleic Acids, 2024 - cell.com
Congenital central hypoventilation syndrome (CCHS), a rare genetic disease caused by
heterozygous PHOX2B mutations, is characterized by life-threatening breathing …

Understanding and treating niemann–pick type c disease: Models matter

V Pallottini, FW Pfrieger - International Journal of Molecular Sciences, 2020 - mdpi.com
Biomedical research aims to understand the molecular mechanisms causing human
diseases and to develop curative therapies. So far, these goals have been achieved for a …

Current advancements in therapy for Niemann-Pick disease: Progress and pitfalls

T Bremova-Ertl, S Schneider - Expert opinion on pharmacotherapy, 2023 - Taylor & Francis
ABSTRACT Introduction Niemann-Pick disease type C (NPC) is a rare, autosomal recessive,
lysosomal storage disorder. To combat the progressive neurodegeneration in NPC, disease …

[HTML][HTML] Quantitative analysis of the proteome response to the histone deacetylase inhibitor (HDACi) vorinostat in Niemann-Pick Type C1 disease

K Subramanian, N Rauniyar, M Lavalleé-Adam… - Molecular & Cellular …, 2017 - Elsevier
Niemann-Pick type C (NPC) disease is an inherited, progressive neurodegenerative
disorder principally caused by mutations in the NPC1 gene. NPC disease is characterized …